Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR trial of nadofaragene firadenovec for low-grade upper tract urothelial carcinoma
NL-OMON59839Phase 2Not yet recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nadofaragene firadenovec in upper tract urothelial carcinoma (UTUC), sponsored by Ferring Pharmaceuticals. Primary endpoints: Primary Safety Endpoint and Primary Efficacy Endpoint. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NL-OMON59839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59839.